RU2018121249A - Анализы и способы для выбора схемы лечения для индивидуума с лейкозом - Google Patents
Анализы и способы для выбора схемы лечения для индивидуума с лейкозом Download PDFInfo
- Publication number
- RU2018121249A RU2018121249A RU2018121249A RU2018121249A RU2018121249A RU 2018121249 A RU2018121249 A RU 2018121249A RU 2018121249 A RU2018121249 A RU 2018121249A RU 2018121249 A RU2018121249 A RU 2018121249A RU 2018121249 A RU2018121249 A RU 2018121249A
- Authority
- RU
- Russia
- Prior art keywords
- mutation
- individual
- flt
- cpx
- gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (21)
1. Комбинация CPX-351 и ингибитора FLT-3 для применения в способе лечения гемобластоза у индивидуума с гемобластозом,
включающем введение эффективного количества указанной комбинации CPX-351 и ингибитора FLT-3.
2. Комбинация по п.1, где указанный индивидуум имеет мутацию гена Fms-подобной рецепторной тирозинкиназы 3 (FLT-3).
3. Комбинация по п.2, где мутация является активирующей мутацией гена FLT-3.
4. Комбинация по п.1, где в указанном способе ингибитор CPX-351 и FLT-3 вводят одновременно, или где CPX-351 вводят перед лечением ингибитором FLT-3, или где CPX-351 и ингибитор FLT-3 вводят в одной композиции.
5. Комбинация по п.1, где гемобластоз выбран из группы, состоящей из острого миелогенного лейкоза (AML), острого лимфоцитарного лейкоза (ALL), хронического лимфоцитарного лейкоза (CLL), хронического миелолейкоза (CML), миелопролиферативных неоплазий (MPN) и лимфом.
6. Комбинация по любому из пп.1-5, где ингибитором FLT-3 является квизартиниб, мидостаурин, тандутиниб, сорафениб, сунитиниб, лестауртиниб, креноланиб, гилтеритиниб, AST-487, довитиниб или линифаниб.
7. CPX-351 для применения в способе лечения гемобластоза у индивидуума, включающем:
(a) определение наличия или отсутствия мутации гена Fms-подобной рецепторной тирозинкиназы 3 (FLT-3) у указанного индивидуума и введение эффективного количества CPX-351 индивидууму, имеющему мутацию указанного гена FLT-3;и/или
(b) определение наличия или отсутствия мутации гена нуклеофозмина 1 (NPM-1) у указанного индивидуума и введение эффективного количества CPX-351 индивидууму, имеющему мутацию указанного гена NPM-1;и/или
(c) определение наличия или отсутствия мутации гена CCAAT-энхансерного связывающего белка альфа (CEBPα) у указанного индивидуума и введение эффективного количества CPX-351 индивидууму, имеющему мутацию указанного гена CEBPα; и/или
(d) определение генотипа указанного индивидуума, как имеющего благоприятный риск, промежуточный-I, промежуточный-II или неблагоприятный риск, и введение терапевтически эффективного количества CPX-351 индивидууму, генотип которого соответствует неблагоприятному риску или промежуточному-II.
8. Способ определения восприимчивости человека с гемобластозом к лечению CPX-351, включающий анализ биологического образца указанного индивидуума для определения:
a) наличия или отсутствия мутации гена Fms-подобной рецепторной тирозинкиназы 3 (FLT-3) у указанного индивидуума; и/или
b) наличия или отсутствия мутации гена нуклеофозмина 1 (NPM-1) у указанного индивидуума; и/или
c) наличия или отсутствия мутации гена CCAAT-энхансерного связывающего белка альфа (CEBPα) у указанного индивидуума; и/или
d) генотипа указанного индивидуума, как имеющего благоприятный риск, промежуточный-I, промежуточный-II или неблагоприятный риск.
9. Способ по п. 8, где гемобластоз выбран из группы, состоящей из острого миелогенного лейкоза (AML), острого лимфоцитарного лейкоза (ALL), хронического лимфоцитарного лейкоза (CLL), хронического миелолейкоза (CML), миелопролиферативных неоплазий (MPN) и лимфом.
10. Способ по п.8, где мутация (a) является активирующей мутацией FLT-3.
11. Способ по п.10, где мутация является мутацией FLT-3-ITD или FLT-3-TKD.
12. Способ по любому из пп.8-11, где биологический образец содержит кровь, сыворотку, плазму, слюну или бластные клетки.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562254109P | 2015-11-11 | 2015-11-11 | |
US62/254,109 | 2015-11-11 | ||
PCT/US2016/061444 WO2017083592A1 (en) | 2015-11-11 | 2016-11-10 | Assays and methods for selecting a treatment regimen for a subject with leukemia |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2022132753A Division RU2022132753A (ru) | 2015-11-11 | 2016-11-10 | Анализы и способы для выбора схемы лечения для индивидуума с лейкозом |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2018121249A true RU2018121249A (ru) | 2019-12-17 |
RU2018121249A3 RU2018121249A3 (ru) | 2020-03-17 |
RU2786077C2 RU2786077C2 (ru) | 2022-12-16 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
US20230279503A1 (en) | 2023-09-07 |
AU2022291559A1 (en) | 2023-02-02 |
BR112018009463A2 (pt) | 2018-11-06 |
US20210246512A1 (en) | 2021-08-12 |
KR20180108572A (ko) | 2018-10-04 |
US10927418B2 (en) | 2021-02-23 |
US20180327854A1 (en) | 2018-11-15 |
JP6976941B2 (ja) | 2021-12-08 |
CN115414376A (zh) | 2022-12-02 |
CA3005076C (en) | 2024-01-02 |
HK1258724A1 (zh) | 2019-11-15 |
AU2016353163A1 (en) | 2018-06-07 |
EP3373919A4 (en) | 2019-06-19 |
MX2018005771A (es) | 2019-03-14 |
AU2016353163B2 (en) | 2022-09-29 |
CN108778260A (zh) | 2018-11-09 |
US11746386B2 (en) | 2023-09-05 |
IL259271B (en) | 2022-05-01 |
SG10202112699UA (en) | 2021-12-30 |
SG11201804020YA (en) | 2018-06-28 |
CA3219061A1 (en) | 2017-05-18 |
CO2018005846A2 (es) | 2018-08-21 |
WO2017083592A1 (en) | 2017-05-18 |
EP3373919A1 (en) | 2018-09-19 |
CA3005076A1 (en) | 2017-05-18 |
JP2018535975A (ja) | 2018-12-06 |
BR112018009463A8 (pt) | 2019-02-26 |
IL292080A (en) | 2022-06-01 |
JP2022024031A (ja) | 2022-02-08 |
RU2018121249A3 (ru) | 2020-03-17 |
IL259271A (en) | 2018-07-31 |
MY193531A (en) | 2022-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2014118741A (ru) | Композиции для лечения ревматоидного артрита и способы их применения | |
Cai et al. | LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. | |
Ashton et al. | Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells | |
Mattei et al. | Targeted therapy in metastatic renal carcinoma | |
EA201591932A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ | |
JP2017036288A5 (ru) | ||
RS54156B1 (en) | COMBINED THERAPY INCLUDING ALFA5BETA1 ANTAGONISTS | |
JP2016510316A5 (ru) | ||
Sun et al. | Brain‐derived neurotrophic factor is a potential osteoclast stimulating factor in multiple myeloma | |
BR112021014854A2 (pt) | Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis | |
DK1711185T3 (da) | Kombination af roscovitin-CS-682 eller dens metabolit CNDAC | |
Advani | FLT3 and acute myelogenous leukemia: biology, clinical significance and therapeutic applications | |
RU2018121249A (ru) | Анализы и способы для выбора схемы лечения для индивидуума с лейкозом | |
RU2014123166A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
Zhang et al. | A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation | |
EA202191984A1 (ru) | Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза | |
RU2022132753A (ru) | Анализы и способы для выбора схемы лечения для индивидуума с лейкозом | |
Duyvestyn et al. | Dasatinib promotes the activation of quiescent hematopoietic stem cells in mice | |
Haznedaroğlu | Current management of chronic myeloid leukemia with tyrosine kinase inhibitors | |
Li et al. | Interferon-α Based Individualized Treatment of a High Risk Chronic Myelogenous Leukemia Patient Harboring T315I Mutation. | |
Maeda et al. | Improved drug adherence in patients with chronic myeloid leukemia in the chronic phase by switching to second-generation tyrosine kinase inhibitors | |
ATE454153T1 (de) | 5-ht4 antagonisten zur behandlung von herzversagen | |
MA39693B1 (fr) | Association entre le 3-[(3-{[4-(4-morpholinylméthyl)-1h-pyrrol-2-yl]méthylène}-2-oxo-2,3-dihydro-1h-indol-5-yl)méthyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr | |
RU2014110271A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
Tang et al. | Does an immediate commencement of pulmonary rehabilitation following hospitalization for an exacerbation of chronic obstructive pulmonary disease positively impact attendance and completion rates: a pilot randomized controlled trial? |